• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 3. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 4. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 5. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Phenylpyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Phenylpyrimidines

6-(4-Methoxyphenyl)pyrimidine-2,4(1H,3H)-dione: A Comprehensive Overview

Pyrimidines are a class of heterocyclic compounds that have garnered significant attention in the field of biomedical research. Among these, 6-(4-Methoxyphenyl)pyrimidine-2,4(1H,3H)-dione stands out as a compound with unique structural features and potential therapeutic applications. This molecule belongs to the family of pyrimidine derivatives, which have been extensively studied for their role in cancer research, inflammation, and neurodegenerative diseases.

The compound's structure features a pyrimidine ring substituted with a 4-methoxyphenyl group. The pyrimidine core is further functionalized at positions 2 and 4 with ketone groups, making it a dione. This unique combination of structural elements endows the molecule with distinct pharmacological properties. Recent studies have highlighted its potential as an anticancer agent, particularly in targeting Aurora kinase and CDKs (Cyclin-Dependent Kinases).

In the realm of cancer therapy, the development of targeted therapies has become a focal point. Pyrimidine-based compounds have emerged as promising candidates due to their ability to modulate key signaling pathways involved in cell proliferation and survival. The presence of the methoxy group at position 4 of the phenyl ring introduces additional complexity, potentially influencing the molecule's bioavailability, metabolism, and selectivity.

Recent advancements in molecular modeling and in silico drug design have enabled researchers to gain deeper insights into the binding interactions of this compound with its target proteins. For instance, studies using MDCK (M docking software) have demonstrated that 6-(4-Methoxyphenyl)pyrimidine-2,4(1H,3H)-dione exhibits high affinity for BRAF kinase, a critical regulator of the MAPK/ERK pathway. This interaction has been linked to its potential as an inhibitor of cancer cell migration and invasion.

Another area of active research is the evaluation of this compound's effects on inflammatory pathways. Pyrimidine derivatives have shown promise in modulating CNF-κB signaling, which plays a pivotal role in chronic inflammation and associated diseases such as rheumatoid arthritis and cancer. Preclinical studies indicate that 6-(4-Methoxyphenyl)pyrimidine-2,4(1H,3H)-dione may act as an anti-inflammatory agent by inhibiting the nuclear translocation of NF-κB.

The development of novel therapeutic strategies for neurodegenerative diseases remains a major challenge in contemporary medicine. Emerging evidence suggests that pyrimidine-based compounds may hold potential in this domain as well. Specifically, research has explored the compound's effects on dopamine receptors, which are implicated in the pathophysiology of Parkinson's disease and other movement disorders.

From a pharmacokinetic perspective, the methoxy group at position 4 of the phenyl ring may influence the compound's absorption, distribution, m metabolism, excretion, and toxicity. These factors are critical in determining its therapeutic index and safety profile. Advanced techniques such as LCS (liquid chromatography-mass spectrometry) have been employed to study the pharmacokinetics of this compound in preclinical models.

The application of AI-driven drug discovery has revolutionized the identification of novel therapeutic agents. Machine learning algorithms have been utilized to predict the potential biological activities of 6-(4-Methoxyphenyl)pyrimidine-2,4(1H,3H)-dione and guide its optimization for improved efficacy and safety. Such approaches hold promise for accelerating the development of this compound as a next-generation therapeutic.

In summary, 6-(4-Methoxyphenyl)pyrimidine-2,4(1H,3H)-dione represents a compelling candidate for further investigation in the field of biochemical research. Its unique structural features and diverse biological activities position it as a potential agent for treating cancer, inflammation, and neurodegenerative diseases. Ongoing studies aim to elucidate its mechanisms of action, optimize its pharmacokinetic properties, and evaluate its therapeutic efficacy in clinical settings.

• 116137-74-7(6-(2-Methoxyphenyl)pyrimidine-2,4(1H,3H)-dione)
• 13345-09-0(6-phenylpyrimidine-2,4-diol)
• 94937-24-3(6-(4-Methoxyphenyl)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione)
• 105202-44-6(2,4(1H,3H)-Pyrimidinedione, 6-(3-methoxyphenyl)-1,3-dimethyl-)
• 33166-96-0(6-(p-tolyl)pyrimidine-2,4(1H,3H)-dione)
• 61736-36-5(3-methyl-6-phenyl-1,2,3,4-tetrahydropyrimidine-2,4-dione)
• 1368650-74-1(6-(4-Ethoxyphenyl)pyrimidine-2,4(1H,3H)-dione)
• 33166-92-6(6-(3-Methoxyphenyl)pyrimidine-2,4(1H,3H)-dione)
• 5349-42-8(2,4-Imidazolidinedione,5-[(4-methoxyphenyl)methylene]-)
• 118267-11-1(3-methyl-6-(4-methylphenyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione)